AirSculpt Technologies, Inc. Annual Report: A Year in Review

This guide breaks down how AirSculpt Technologies performed this past year. Use this "cheat sheet" to decide if this company fits your investment goals.

1. What does this company do?

AirSculpt performs body contouring. Instead of traditional surgery, they use a patented method that avoids needles, scalpels, stitches, and general anesthesia. They remove fat and offer "fat transfer" procedures—like the Power BBL® or Up a Cup™—to enhance specific areas using the patient's own fat. As of late 2025, the company operates 27 U.S. centers. They provide these elective cosmetic services directly to consumers, avoiding the complexities of insurance.

2. Financial performance

It was a difficult year for the company. Revenue fell to $151.8 million in 2025, a 15.8% drop from $180.4 million in 2024. This decline happened because case volume dropped from roughly 14,080 cases in 2024 to 11,851 in 2025. Because patients pay 100% upfront, the company avoids insurance headaches but is clearly feeling the pressure of lower demand. They averaged $12,809 per procedure, nearly identical to the previous year.

3. Financial health and debt

The company is currently under tight financial constraints. They have $75.8 million in total debt. Because revenue fell, they renegotiated their loan agreement in early 2025. This deal required them to pay down $20 million of debt and maintain a cash cushion of at least $7.5 million. Furthermore, the company lost $28.4 million in 2025, compared to a $5.2 million profit in 2024. Their expenses are currently outpacing their income.

4. Major risks to watch

• Economic Sensitivity: These procedures are expensive and elective. With an average cost over $12,000, they are often the first items cut from household budgets when inflation or interest rates rise.
• Financing Reliance: About half of their patients use third-party financing to pay for procedures. If these lenders tighten credit standards or raise interest rates, the company may struggle to book new surgeries.
• Geographic Concentration: A massive 20% of their revenue comes from just five centers in Southern California. A local economic downturn or new regulations in that region could significantly hurt the company’s total revenue.
• Insurance & Legal: The company faces risks regarding medical malpractice. Rising insurance premiums or potential lawsuits could lead to unexpected costs that drain their cash reserves.
• Sponsor Influence: Their private equity sponsor, OrbiMed, owns 47% of the company. This gives them the power to control the board and strategy, which may prioritize their own goals over the interests of smaller retail shareholders.

5. Future outlook

The company is in "survival and stabilization" mode. They stopped opening new centers in 2025 to save cash and pay down debt. Management now focuses on improving the performance of existing centers through better marketing and surgeon utilization. They hope that offering flexible financing will help them return to positive cash flow by the end of 2026.

Bottom Line: AirSculpt is navigating a difficult period of falling revenue and high debt. While they have taken steps to stabilize their finances, they remain vulnerable to economic shifts, changes in consumer credit, and the performance of their Southern California market. Before investing, consider whether you believe the company can successfully pivot back to profitability under these current constraints.